Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to investigate the use of radiolabeled particulate cholesterol administered intravenously in association with albumin, as a method to study reverse cholesterol transport (RCT) in people carrying mutations in genes known to affect high density lipoprotein (HDL) metabolism by analyzing changes in the tracer activity in total plasma, lipoproteins fractions and feces.


Clinical Trial Description

The study will use 3H-cholesterol bound to albumin (particulate cholesterol) to assess the ability of HDL to transport cholesterol from the periphery to the liver to be eliminated. This process is called reverse cholesterol transport (RCT) and is one of the main mechanisms by which HDL protect against atherosclerotic cardiovascular disease. Mutations in some of the genes affecting HDL metabolism, may results in changes in RCT. The validation of a method assessing RCT is important for the development of new drugs which affect RCT and may result in useful treatments for atherosclerosis. Subjects carrying mutations in genes known to affect HDL metabolism and healthy controls will be enrolled in the study. Changes in the tracer activity in total plasma, lipoproteins fractions and feces will be analyzed following the intravenous administration of radiolabeled particulate cholesterol. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01782027
Study type Interventional
Source University of Pennsylvania
Contact
Status Suspended
Phase N/A
Start date October 2012
Completion date July 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT00092898 - An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED) Phase 3
Completed NCT00004481 - Genetic Study of Sitosterolemia N/A
Completed NCT00477594 - Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Phase 2
Not yet recruiting NCT02707211 - Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases Phase 0
Active, not recruiting NCT05425745 - Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. Phase 3
Completed NCT00607373 - Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Phase 3
Completed NCT00362180 - Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Phase 2
Terminated NCT00092833 - Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED) Phase 3
Active, not recruiting NCT02635269 - Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy N/A
Terminated NCT00260299 - Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency
Completed NCT00092820 - Sitosterolemia Extension Study (0653-004)(COMPLETED) Phase 3
Completed NCT00092807 - Sitosterolemia Extension Study (0653-003)(COMPLETED) Phase 3
Completed NCT00694109 - An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia Phase 3